...
首页> 外文期刊>Cardiovascular Diabetology >Dyslipidemia in primary care – prevalence, recognition, treatment and control: data from the German Metabolic and Cardiovascular Risk Project (GEMCAS)
【24h】

Dyslipidemia in primary care – prevalence, recognition, treatment and control: data from the German Metabolic and Cardiovascular Risk Project (GEMCAS)

机译:初级保健中的血脂异常–患病率,识别率,治疗率和控制率:来自德国代谢和心血管风险项目(GEMCAS)的数据

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background Current guidelines from the European Society of Cardiology (ESC) define low thresholds for the diagnosis of dyslipidemia using total cholesterol (TC) and LDL-cholesterol (LDL-C) to guide treatment. Although being mainly a prevention tool, its thresholds are difficult to meet in clinical practice, especially primary care. Methods In a nationwide study with 1,511 primary care physicians and 35,869 patients we determined the prevalence of dyslipidemia, its recognition, treatment, and control rates. Diagnosis of dyslipidemia was based on TC and LDL-C. Basic descriptive statistics and prevalence rate ratios, as well as 95% confidence intervals were calculated. Results Dyslipidemia was highly frequent in primary care (76% overall). 48.6% of male and 39.9% of female patients with dyslipidemia was diagnosed by the physicians. Life style intervention did however control dyslipidemia in about 10% of patients only. A higher proportion (34.1% of male and 26.7% female) was controlled when receiving pharmacotherapy. The chance to be diagnosed and subsequently controlled using pharmacotherapy was higher in male (PRR 1.15; 95%CI 1.12–1.17), in patients with concomitant cardiovascular risk factors, in patients with hypertension (PRR 1.20; 95%CI 1.05–1.37) and cardiovascular disease (PRR 1.46; 95%CI 1.29–1.64), previous myocardial infarction (PRR 1.32; 95%CI 1.19–1.47), and if patients knew to be hypertensive (PRR 1.18; 95%CI 1.04–1.34) or knew about their prior myocardial infarction (PRR 1.17; 95%CI 1.23–1.53). Conclusion Thresholds of the ESC seem to be difficult to meet. A simple call for more aggressive treatment or higher patient compliance is apparently not enough to enhance the proportion of controlled patients. A shift towards a multifactorial treatment considering lifestyle interventions and pharmacotherapy to reduce weight and lipids may be the only way in a population where just to be normal is certainly not ideal.
机译:背景技术欧洲心脏病学会(ESC)的当前指南使用总胆固醇(TC)和LDL-胆固醇(LDL-C)指导治疗定义了血脂异常的低阈值。尽管它主要是一种预防工具,但其阈值在临床实践中尤其是初级保健中很难达到。方法在一项涉及1,511名初级保健医生和35,869名患者的全国性研究中,我们确定了血脂异常的患病率,识别率,治疗率和控制率。血脂异常的诊断基于TC和LDL-C。计算了基本描述统计和患病率比率以及95%的置信区间。结果血脂异常在基层医疗中很常见(总体占76%)。医生诊断出血脂异常的男性患者中有48.6%,女性患者中有39.9%。但是,生活方式干预仅能控制约10%的患者血脂异常。接受药物治疗时,控制了较高的比例(男性为34.1%,女性为26.7%)。男性(PRR 1.15; 95%CI 1.12–1.17),伴有心血管危险因素的患者,高血压患者(PRR 1.20; 95%CI 1.05–1.37)和男性,接受药物治疗的可能性更高。心血管疾病(PRR 1.46; 95%CI 1.29-1.64),先前的心肌梗塞(PRR 1.32; 95%CI 1.19-1.47)以及患者是否知道高血压(PRR 1.18; 95%CI 1.04–1.34)或知道他们先前的心肌梗塞(PRR 1.17; 95%CI 1.23–1.53)。结论ESC的阈值似乎很难达到。简单地呼吁采取更积极的治疗或提高患者的依从性显然不足以增加受控患者的比例。在考虑到生活方式干预和药物疗法以减轻体重和血脂的情况下,转向多因素治疗可能是在正常情况下绝对不理想的人群的唯一方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号